Drug Trial Radar · NCT06780098
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
May 28, 2025
Primary completion
Mar 2, 2032
Study completion Mar 2, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body. Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC. Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goals of this study are to learn about: * The cancer response to the study treatments compared to chemotherapy * The safety of the study treatments and if people tolerate them This study is one of the substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
Conditions
- Lung Neoplasm
Interventions
R-DXDBiological
IV Infusion
I-DXDBiological
IV Infusion
DocetaxelDrug
IV Infusion
Rescue MedicationsDrug
Participants receive rescue medications consisting of a combination regimen to include corticosteroids with a 5-hydroxytryptamine subtype 3 receptor antagonist and/or a neurokinin-1 receptor antagonist, all per approved product label and following institutional standards or local guidelines.
Rescue MedicationDrug
Participants are premedicated with corticosteroids per approved product label and following institutional standards or local guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to approximately 81 months
- Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 81 months
- Number of participants who discontinue study intervention due to an AETime frame: Up to approximately 81 months
Locations
46 sites in 11 countries. Site status is shown where the registry gives one.
University of Kentucky Chandler Medical Center ( Site 0019)
Lexington, Kentucky · Recruiting
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, Maryland · Recruiting
Texas Oncology - DFW ( Site 8003)
Dallas, Texas · Recruiting
Virginia Cancer Specialists (VCS) ( Site 0408)
Fairfax, Virginia · Recruiting
Centro de Estudios Clínicos SAGA ( Site 0161)
Santiago, Region M. de Santiago, Chile · Recruiting
Fundación Arturo López Pérez ( Site 0160)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0162)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Cancer Hospital ( Site 0301)
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital ( Site 0304)
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Provincial Cancer Hospital ( Site 0310)
Fuzhou, Fujian, China · Recruiting
Guangxi Medical University Cancer Hospital ( Site 0303)
Nanning, Guangxi, China · Recruiting
Henan Cancer Hospital ( Site 0311)
Zhengzhou, Henan, China · Recruiting
Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 0309)
Nanjing, Jiangsu, China · Recruiting
Shanghai Chest Hospital ( Site 0308)
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital ( Site 0300)
Shanghai, Shanghai Municipality, China · Recruiting
Charite-Universitaetsmedizin Berlin ( Site 0191)
Berlin, Germany · Recruiting
UniversitaetsklInikum Tuebingen ( Site 0192)
Tübingen, Baden-Wurttemberg, Germany · Recruiting
European Interbalkan Medical Center-Oncology Department ( Site 0205)
Thessaloniki, Greece · Recruiting
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)
Athens, Attica, Greece · Recruiting
F. THERAPIS GENERAL ( Site 0206)
Athens, Attica, Greece · Recruiting
Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063)
Kecskemét, Bács-Kiskun county, Hungary · Recruiting
Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)
Győr, Győr-Moson-Sopron, Hungary · Recruiting
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)
Szolnok, Jász-Nagykun-Szolnok, Hungary · Recruiting
Rambam Health Care Campus ( Site 0076)
Haifa, Israel · Recruiting
Shaare Zedek Medical Center ( Site 0075)
Jerusalem, Israel · Recruiting
Meir Medical Center ( Site 0071)
Kfar Saba, Israel · Recruiting
Rabin Medical Center ( Site 0074)
Petah Tikva, Israel · Recruiting
Sheba Medical Center ( Site 0070)
Ramat Gan, Israel · Recruiting
Sourasky Medical Center ( Site 0077)
Tel Aviv, Israel · Recruiting
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Italy · Recruiting
IRCCS Ospedale San Raffaele ( Site 0171)
Milan, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
Milan, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
Roma, Italy · Recruiting
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153)
Poznan, Greater Poland Voivodeship, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Pomeranian Voivodeship, Poland · Recruiting
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0152)
Koszalin, West Pomeranian Voivodeship, Poland · Recruiting
Hospital Universitario Quiron Madrid ( Site 0091)
Madrid, Spain · Recruiting
Hospital Universitario Virgen Macarena ( Site 0094)
Seville, Spain · Recruiting
Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.